文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

黑色素瘤治疗中的细胞死亡方式

Cell Death Modalities in Therapy of Melanoma.

作者信息

Wang Meng, Zhao Jia-Hui, Tang Ming-Xuan, Li Meng, Zhao Hu, Li Zhong-Yu, Liu An-Dong

机构信息

Department of Human Anatomy, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

National Demonstration Center for Experimental Basic Medical Education, Huazhong University of Science and Technology, Wuhan 430030, China.

出版信息

Int J Mol Sci. 2025 Apr 8;26(8):3475. doi: 10.3390/ijms26083475.


DOI:10.3390/ijms26083475
PMID:40331942
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12026598/
Abstract

Melanoma, one of the most lethal cancers, demands urgent and effective treatment strategies. However, a successful therapeutic approach requires a precise understanding of the mechanisms underlying melanoma initiation and progression. This review provides an overview of melanoma pathogenesis, identifies current pathogenic factors contributing to mortality, and explores targeted therapy and checkpoint inhibitor therapy. Furthermore, we examine melanoma classification and corresponding therapies, along with advancements in various cell death mechanisms for melanoma treatment. We also discuss the current treatment status along with some drawbacks encountered during research stages such as resistance and metastasis.

摘要

黑色素瘤是最致命的癌症之一,需要紧急且有效的治疗策略。然而,一种成功的治疗方法需要精确了解黑色素瘤起始和进展的潜在机制。本综述概述了黑色素瘤的发病机制,确定了导致死亡的当前致病因素,并探讨了靶向治疗和检查点抑制剂治疗。此外,我们研究了黑色素瘤的分类及相应治疗方法,以及黑色素瘤治疗中各种细胞死亡机制的进展。我们还讨论了当前的治疗现状以及在研究阶段遇到的一些缺点,如耐药性和转移。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/67e07ff1a383/ijms-26-03475-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/1ca41d31dd1d/ijms-26-03475-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/b10d81b00f9d/ijms-26-03475-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/2d7ffa4eaf0e/ijms-26-03475-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/1648dba9781a/ijms-26-03475-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/f8082b541b0c/ijms-26-03475-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/0cd562ea4a45/ijms-26-03475-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/fa3dc089603d/ijms-26-03475-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/67e07ff1a383/ijms-26-03475-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/1ca41d31dd1d/ijms-26-03475-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/b10d81b00f9d/ijms-26-03475-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/2d7ffa4eaf0e/ijms-26-03475-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/1648dba9781a/ijms-26-03475-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/f8082b541b0c/ijms-26-03475-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/0cd562ea4a45/ijms-26-03475-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/fa3dc089603d/ijms-26-03475-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bd2/12026598/67e07ff1a383/ijms-26-03475-g008.jpg

相似文献

[1]
Cell Death Modalities in Therapy of Melanoma.

Int J Mol Sci. 2025-4-8

[2]
Advanced Melanoma: Resistance Mechanisms to Current Therapies.

Hematol Oncol Clin North Am. 2021-2

[3]
Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma.

Cancer J. 2017

[4]
Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes.

Front Immunol. 2024

[5]
PARP1 in melanoma: Mechanistic insights and implications for basic and clinical research.

Cancer Lett. 2025-5-1

[6]
Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.

Front Immunol. 2021

[7]
Safety and Efficacy Analysis of Targeted and Immune Combination Therapy in Advanced Melanoma-A Systematic Review and Network Meta-Analysis.

Int J Mol Sci. 2024-11-28

[8]
Determinants of resistance and response to melanoma therapy.

Nat Cancer. 2024-7

[9]
Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma Therapy.

Curr Oncol Rep. 2024-7

[10]
Advancing immunotherapy for melanoma: the critical role of single-cell analysis in identifying predictive biomarkers.

Front Immunol. 2024

引用本文的文献

[1]
Programmed cell death-driven remodeling of the melanoma microenvironment enables prognostic stratification and therapeutic prediction.

Front Immunol. 2025-8-20

[2]
Chloroquine as a potential anticancer agent for triple-negative breast cancer: effects on MDA-MB-231 cells.

Med Oncol. 2025-6-8

本文引用的文献

[1]
Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma.

Front Immunol. 2024

[2]
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.

N Engl J Med. 2025-1-2

[3]
Malignant Melanoma: An Overview, New Perspectives, and Vitamin D Signaling.

Cancers (Basel). 2024-6-18

[4]
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

N Engl J Med. 2024-11-7

[5]
Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists.

Int J Mol Sci. 2024-4-30

[6]
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.

Eur J Cancer. 2024-6

[7]
Emerging dimensions of autophagy in melanoma.

Autophagy. 2024-8

[8]
Photo-neuro-immuno-endocrinology: How the ultraviolet radiation regulates the body, brain, and immune system.

Proc Natl Acad Sci U S A. 2024-4-2

[9]
Elesclomol Loaded Copper Oxide Nanoplatform Triggers Cuproptosis to Enhance Antitumor Immunotherapy.

Adv Sci (Weinh). 2024-5

[10]
BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition.

Mil Med Res. 2023-12-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索